Cancer Vaccines

Phase I Trial Results in Hybrid Cell Vaccine for Metastatic Melanoma

Published in Gene Therapy Weekly, November 17th, 1997

Encouraging results from a Phase I clinical trial suggests that hybrid cell vaccines may be a novel treatment for metastatic melanoma.

Research has confirmed that tumor cells escape the host's immune surveillance system because they do not provide the essential signals for the activation of the host immune system. Vaccinating patients with tumor cells, modified so that the immune system recognizes them, is one method of bypassing this problem. Several vaccines have undergone scrutiny.

Hybrid cell vaccines incorporate a fusion of tumor cells and activated allogeneic B cells. These vaccines are designed to activate effector cytolytic T cells which...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-11-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry